Related Experiment Video
Updated: Aug 2, 2026
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Phosphatidylserine suppresses myelin-induced experimental allergic neuritis (EAN) in Lewis rats
Y Maeda1, R Maeda, J W Prineas
1Department of Neurosciences, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark 07103.
Abstract:
Phosphatidylserine administered as an aqueous dispersion to myelin-induced experimental allergic neuritis rats had a significant effect on disease course. Intraperitoneal injections of 30 mg/kg were given daily beginning at the onset of disease and continued for 14 days. Clinical severity and mortality were markedly reduced by this treatment as compared to saline controls. Improved clinical outcome was associated with a reduction in peripheral nerve pathology. A possible mechanism involving tumor necrosis factor is discussed.
Insights
Phosphatidylserine treatment significantly reduced disease severity and mortality in rats with experimental allergic neuritis. This neuroprotective effect was linked to reduced peripheral nerve damage, suggesting a potential therapeutic role.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Experimental allergic neuritis (EAN) is an autoimmune disease model of demyelinating polyneuropathy.
- Phosphatidylserine is a phospholipid with potential immunomodulatory and neuroprotective properties.
Purpose of the Study:
- To investigate the therapeutic efficacy of phosphatidylserine in a rat model of experimental allergic neuritis.
- To assess the impact of phosphatidylserine on clinical disease course, mortality, and peripheral nerve pathology in EAN.
Main Methods:
- Rats with myelin-induced EAN received daily intraperitoneal injections of phosphatidylserine (30 mg/kg) starting at disease onset for 14 days.
- Clinical severity scores and mortality rates were monitored and compared to saline-treated control groups.
- Peripheral nerve pathology was evaluated to correlate with clinical outcomes.
Main Results:
- Phosphatidylserine treatment significantly reduced clinical severity compared to controls.
- A marked reduction in mortality was observed in the phosphatidylserine-treated group.
- Improved clinical outcomes correlated with decreased peripheral nerve pathology.
Conclusions:
- Phosphatidylserine demonstrates significant therapeutic potential in experimental allergic neuritis.
- The neuroprotective effects may involve modulation of inflammatory pathways, potentially including tumor necrosis factor.
- Further research into phosphatidylserine's mechanism of action in demyelinating diseases is warranted.
More Related Videos
07:30A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
09:46Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
Published on: September 21, 2021